Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma

Masao Honda1,2*, Taro Yamashita1, Tatsuya Yamashita1, Kunlaki Arai1, Yoshio Sakai1, Akito Sakai1, Mikiko Nakamura1, Eishiro Mizukoshi1 and Shuichi Kaneko1

Abstract

Background: The acyclic retinoid, peretinoin, has been shown to be effective for suppressing hepatocellular carcinoma (HCC) recurrence after definitive treatment in a small-scale randomized clinical trial. However, little has been documented about the mechanism by which peretinoin exerts its inhibitory effects against recurrent HCC in humans in vivo.

Methods: Twelve hepatitis C virus-positive patients whose HCC had been eradicated through curative resection or ablation underwent liver biopsy at baseline and week 8 of treatment with either a daily dose of 300 or 600 mg peretinoin. RNA isolated from biopsy samples was subjected to gene expression profile analysis.

Results: Peretinoin treatment elevated the expression levels of IGFBP6, RBP1, PRB4, CEBPA, G0S2, TGM2, GPRC5A, CYP26B1, and many other retinoid target genes. Elevated expression was also observed for interferon-, Wnt-, and tumor suppressor-related genes. By contrast, decreased expression levels were found for mTOR- and tumor progression-related genes. Interestingly, gene expression profiles for week 8 of peretinoin treatment could be classified into two groups of recurrence and non-recurrence with a prediction accuracy rate of 79.6% (P<0.05). In the liver of patients with non-recurrence, expression of PDGFC and other angiogenesis genes, cancer stem cell marker genes, and genes related to tumor progression was down-regulated, while expression of genes related to hepatocyte differentiation, tumor suppression genes, and other genes related to apoptosis induction was up-regulated.

Conclusions: Gene expression profiling at week 8 of peretinoin treatment could successfully predict HCC recurrence within 2 years. This study is the first to show the effect of peretinoin in suppressing HCC recurrence in vivo based on gene expression profiles and provides a molecular basis for understanding the efficacy of peretinoin.

Keywords: Acyclic retinoid, Gene expression, Hepatocellular carcinoma

Background

Hepatocellular carcinoma (HCC) is the sixth most common form of cancer worldwide, and it is estimated that there are more than 740,000 new cases each year [1]. Early-stage HCC is indicated for definitive treatment by surgical resection or local therapy [2-4]; however, the prognosis of HCC is typically poor, and around 50% of patients experience recurrence within 3 years of definitive therapy [5-7]. Indeed, some researchers estimate that the 3-year recurrence rate is higher than 70% for hepatitis C virus (HCV)-positive patients [8], and past clinical experience with interferon-based therapy, systemic chemotherapy, and other treatment modalities has shown the lack of effective standard therapy for suppressing tumor recurrence after definitive treatment for HCC [9-11].

Peretinoin (NIK-333) has only been reported to suppress HCC recurrence in a small-scale randomized controlled
trial [12] in which patients who were disease-free after definitive treatment received oral administration of 600 mg peretinoin daily for one year. The results showed that peretinoin significantly reduced the incidence of recurrent or new HCC [12] and improved patient survival rates [13]. Based on the results of rat pharmacological studies [14,15] and a phase I clinical study of peretinoin [16], a phase II/III clinical study of peretinoin was conducted in which the doses were set at 300 and 600 mg daily. The study demonstrated that, in the Child-Pugh A subgroup, 600 mg/day peretinoin (n=100) reduced the risk of HCC recurrence or death by approximately 40% compared to placebo (n=106) [hazard ratio (HR)=0.60; 95% confidence interval (CI): 0.40–0.89)] [17]. On the other hand, 300 mg daily doses of peretinoin were insufficient for tumor control and showed no substantial difference from the placebo [17]. A large-scale clinical study including several countries is now planned to confirm the clinical efficacy of peretinoin.

Little is known about the mechanism by which peretinoin exerts its inhibitory effects against recurrent HCC in humans in vivo. In order to investigate this mechanism, we conducted here a comparative study recruiting HCV-positive patients who successfully completed definitive treatment for HCC (similar to the phase II/III clinical study mentioned above). Patients underwent liver biopsy before and after 8 weeks of treatment with repeated doses of peretinoin, and the collected samples were analyzed for gene expression profiling using the remnant liver after eradication of HCC. We found that changes in the gene expression signature observed in this study help us to understand the means by which peretinoin suppresses HCC, in particular its inhibition against de novo carcinogenesis.

Methods

Patients

We enrolled 12 HCV-positive patients who were cured of their primary and first recurrent HCC by surgical hepatectomy or radiofrequency ablation therapy and other non-surgical local treatments (Table 1). Complete tumor removal was confirmed by dynamic computed tomography (CT) scans. Inclusion criteria were as follows: positive presence of HCV-RNA in the serum; Child-Pugh class A or B liver function; platelet counts ≥50,000/μL; and age ≥20 years. Exclusion criteria included the following: positive for hepatitis B surface antigen; tumor infiltration into the portal vein; use of transarterial embolization or transarterial chemoembolization (TAE/TACE) for definitive therapy; postoperative use of investigational medicinal products, antitumor agents, interferon, or vitamin K2 formulations; blood pressure unmanageable even with medication (systolic pressure ≥160 mmHg or diastolic pressure ≥100 mmHg); complication with renal impairment, cardiovascular disease, diabetes mellitus, autoimmune disease, asthma, or other severe disease; presence of neoplasm; allergy to CT contrast media; allergy to retinoids; history of total gastrectomy; possible pregnancy during study; and lactating mothers.

Study design

This trial was a randomized, parallel-group, open-label study. Twelve eligible patients signed the informed consent form for registration. They were randomized to receive one of the two peretinoin doses: 600 or 300 mg per day. Each dose group consisted of 6 patients. After randomization, patients underwent liver biopsy before the start of peretinoin treatment, then orally received peretinoin twice daily for 8 weeks. At the end of the 8-week therapy, they underwent a second liver biopsy (Figure 1A). The collected biopsy samples were kept in RNeater® solution (Ambion Inc., Austin, TX) at 4°C overnight or longer. Within 3 days, the biopsy samples were removed from the RNeater solution and partially subjected to RNA extraction and purification. The purified RNA samples were stored at −80°C until required for gene expression profiling. The remaining part of the biopsy samples was used to determine the intrahepatic peretinoin concentration. Samples were placed in polypropylene bottles containing 99.5% ethanol, and the air in the bottle was purged with argon. The bottles were tightly closed and stored at −80°C protected from light. Peripheral blood samples were also collected for the analysis of gene expression signatures and to determine plasma peretinoin levels.

After the second biopsy, patients were orally administered peretinoin twice daily for 88 weeks. During the treatment period, patients visited the hospital every 4 weeks for check-ups, drug compliance, and protocol-specified medical examinations. Drug compliance was assessed by pill counts. During the study, use of anticancer agents, interferon, vitamins K and A, and antiviral drugs (e.g., rivabirin) was prohibited. The study was registered at the Japan Pharmaceutical Information Center (JapicCTI-121757). This protocol was approved by the Institutional Review Board of Kanazawa University for clinical investigation following the provisions of Helsinki, Good Clinical Practice guidelines, local laws, and regulations. Written informed consent was obtained from all patients involved in this study. The detail protocol of this study is presented in Additional file 1: Study protocol.

Plasma peretinoin concentration

A 5-mL blood sample was drawn into an EDTA-2Na tube, immediately mixed, and centrifuged to obtain a plasma sample. The air in the sample tubes was replaced with argon, and the tubes were stored at −80°C protected
| Patient no. | Dose (mg/day) | Age | Sex | P/R | Curative treatment | Tumor no. | Tumor histology | Background liver | CP | ALT (U/L) | PLT (×10^4/μL) | MTD (mm) | Prognosis | 2 yrs | 4.5 yrs |
|------------|---------------|-----|-----|-----|-------------------|-----------|----------------|------------------|----|-----------|----------------|----------|-----------|-------|--------|
| 1          | 300           | 70  | F   | P   | RFA               | 15        | m-p            | 4                | 2  | 112       | 7.9            | 70       | Rec       | Rec   | Rec    |
| 2          | 600           | 72  | F   | R   | RFA               | 20        | w              | 4                | 2  | 40        | 7.9            | 20       | Rec       | Rec λ | Rec    |
| 3          | 300           | 58  | M   | P   | resection         | 25        | m-p            | 2                | 1  | 16        | 19.2           | 25       | nonRec    | nonRec | nonRec |
| 4          | 600           | 54  | M   | P   | resection         | 25        | m-p            | 3                | 2  | 57        | 16.4           | 25       | nonRec    | Rec   | Rec    |
| 5          | 600           | 60  | F   | P   | RFA               | 23        | m-p            | 4                | 2  | 23        | 6.4            | 60       | nonRec    | nonRec | nonRec |
| 6          | 300           | 73  | F   | P   | RFA               | 20        | m-p            | 3                | 2  | 31        | 14.2           | 20       | Rec       | Rec λ | Rec λ |
| 7          | 300           | 69  | F   | P   | RFA               | 11        | w-m            | 4                | 1  | 38        | 11.5           | 11       | Rec       | Rec λ | Rec λ |
| 8          | 600           | 74  | F   | P   | RFA               | 16        | m-p            | 4                | 1  | 45        | 5.1            | 16       | nonRec    | Rec   | Rec    |
| 9          | 600           | 65  | M   | R   | RFA               | 10        | m-p            | 2                | 1  | 29        | 16.5           | 10       | nonRec    | nonRec | nonRec |
| 10         | 600           | 59  | M   | P   | resection         | 34        | m-p            | 4                | 2  | 60        | 9.4            | 34       | nonRec    | nonRec | nonRec |
| 11         | 300           | 70  | F   | R   | RFA               | 15        | w-m            | 4                | 2  | 98        | 7              | 15       | nonRec    | nonRec | nonRec |
| 12         | 300           | 66  | M   | P   | RFA               | 15        | m-p            | 4                | 1  | 90        | 10.6           | 15       | nonRec    | nonRec | nonRec |

Dose (mg/day), ALT(U/L), PLT(×10^4/μL), MTD (mm).
F; female, M; male, P; primary HCC, R; (first) recurrent HCC, MTD; maximum tumor diameter, w; well-differentiated, m; moderately differentiated, p; poorly differentiated, F; fibrosis stage, A; activity grade, CP; Child-Pugh classification, ALT; alanine aminotransferase, PLT; platelet.
Rec; recurrence, nonRec; non-recurrence, λ; death.

**Figure 1** Peretinoin pharmacokinetics study design and change of gene expression profiling. A: Peretinoin pharmacokinetics study design. Twelve patients were enrolled in the study and two groups of 6 patients were randomly administered one of two doses of peretinoin (600 or 300 mg per day) for 8 weeks. A liver biopsy was obtained before the start of peretinoin administration and 8 weeks into the treatment. After the second liver biopsy, oral administration of peretinoin twice daily was resumed for 88 weeks. B: Hierarchical clustering analysis of patients using all expressed genes. Patient numbers (Table 1) and peretinoin dose are listed. Patients with HCC recurrence are shown in red and boxed. There was no significant association between hepatic gene expression and HCC recurrence before starting peretinoin treatment, while distinct clusters of patients were observed after week 8 depending on HCC recurrence.
from light. The plasma concentrations of the unchanged form of peretinoin and its lipid-bound form were determined as follows: first, the peretinoin-containing fractions were extracted from the plasma samples, then subjected to derivatization of peretinoin, and the concentration of the derivative was measured by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry.

Liver peretinoin concentration
Collected liver tissue samples were immersed in 99.5% ethanol in containers, and the internal air was replaced with argon. The samples were stored at −80°C protected from light. The liver concentrations of the unchanged form of peretinoin and its lipid-bound form were determined as for the plasma concentrations above.

Microarray analysis
For gene expression profiling of the liver, in-house cDNA microarrays containing a representative panel of 10,000 liver-specific genes (Kanazawa liver chip 10K ver. 2.0) were used. RNA isolation, amplification of antisense RNA, labeling, and hybridization were conducted as previously described [18].

To identify genetic variants, paired t-tests were performed using BRB-Array Tools software (http://linus.nci.nih.gov/BRB-ArrayTools.html) to define P-values <0.05 as gene variants. Hierarchical cluster analysis, exploration of significantly expressed genes, and class prediction were also performed using the BRB-Array Tools.

Hierarchical clustering was carried out using centered correlation and average linkage. The class comparison tool in the BRB-Array Tools was used to extract significantly expressed genes. Genes whose expression levels were significantly different between two groups were located by the t-test at the P<0.002 significance level. Univariate permutation tests were repeated 1,000–2,000 times to control for errors. Class prediction was performed using the above-mentioned significantly differentiated genes as discriminators, and the results were cross-validated using seven algorithms: compound-covariate predictor, diagonal linear discriminant analysis, 1-nearest neighbor, 3-nearest neighbors, nearest centroid, support vector machine, and Bayesian compound covariate. The mean value of the seven success rates for class prediction was defined as the prediction accuracy rate [18].

Pathway analysis was performed using MetaCore™ (Thomson Reuters, New York, NY) and functional ontology enrichment analysis was performed to find differentially expressed pathway using differentially expressed genes [18,19].

The microarray data have been submitted to the Gene Expression Omnibus (GEO) public database at NCBI (Accession No. GSE29302).

Quantitative real-time detection polymerase chain reaction
Quantitative real-time detection polymerase chain reaction (RTD-PCR) was performed using the TaqMan Universal Master Mix (PE Applied Biosystems, Foster City, CA). Primer pairs and probes were purchased from the TaqMan assay reagents library. Standard curves were generated for each assay using RNA derived from normal human liver tissue. Expression data were normalized by GAPDH, and the results are shown as the relative fold expression to the normal liver.

Statistical analysis
Results are expressed as means ± S.D. Significance was tested by one-way ANOVA with Bonferroni’s method, and differences were considered statistically significant at P<0.05.

Results
Safety
In this study, 88 adverse events were recorded in 12 patients (100%). Major adverse events included rhinopharyngitis (n=7), blood pressure elevation (n=5), peripheral edema (n=3), and enteritis (n=3). Most of these adverse events were mild or moderate, and were adequately controlled. Nine serious adverse events were documented in 5 patients, including hyperglycemia (n=2) and coronary stenosis (n=1). However, all reported serious adverse events were alleviated with appropriate treatment, and there was no substantial concern identified regarding the safety of peretinoin.

Plasma peretinoin concentration
Plasma peretinoin concentrations were determined at week 8 of treatment. The mean (± SD) plasma concentrations of the unchanged form of peretinoin were 82.3 (± 90.0) and 201.2 (± 111.4) ng/mL at 4 h post-dose and 35.8 (± 49.2) and 29.0 (±17.9) ng/mL at 8 h post-dose for the 300 and 600 mg per day groups, respectively. The plasma concentrations of the unchanged peretinoin measured at 4 h post-dose (= t\text{max}) were dose-dependent. The mean (± SD) plasma concentrations of the lipid-bound form of peretinoin were 1478.8 (± 853.7) and 2789.8 (± 1630.0) ng/mL at 4 h post-dose and 1227.8 (± 942.7) and 2213.2 (± 1156.1) ng/mL at 8 h post-dose for the 300 and 600 mg per day groups, respectively. The plasma concentrations of the lipid-bound form of peretinoin were dose-dependent at 4 and 8 h post-dose.

Liver peretinoin concentration
Liver peretinoin concentrations were determined at week 8 of treatment. The measurements of the liver concentration of the unchanged form of peretinoin were all below the lower limit of quantitation at 4 h post-dose for all 6 patients in the 300 mg per day group. For the
600 mg per day group, 2 patients yielded measurements of 0.052 and 0.059 μg/g, while the remaining 4 patients produced results under the lower limit of quantitation (0.050 μg/g). The mean (± SD) concentrations of the lipid-bound form of peretinoin were 13.7508 (± 11.1097) and 12.8345 (± 8.7048) μg/g for the 300 and 600 mg per day groups, respectively.

Gene expression analysis
To analyze the gene expression signature of the liver tissue, we identified genes whose expression levels were significantly different before and after the start of the peretinoin treatment (Figure 1A). The identified genes were candidates for peretinoin-responsive genes. The phase II/III clinical study showed that a daily dose of 600 mg peretinoin reduced the risk of HCC recurrence, while a 300 mg dose was not significantly different from the placebo [17]. Therefore, gene expression patterns were compared before and after the start of the 600 mg peretinoin therapy (n=6). Consequently, 424 hepatic genes showed significantly different expression levels from baseline at week 8 (enhancement and suppression seen for 190 and 234 genes, respectively). Typical examples of these genes are represented in Table 2 where fold changes of gene expression for the 300 mg and 600 mg doses are shown respectively. In addition to the retinoid-induced genes, genes related to interferon, tumor suppressors, negative regulators of Wnt signaling, insulin-like growth factor (IGF) signaling, and hepatocyte differentiation were significantly up-regulated by peretinoin. By contrast, genes related to the mammalian target of rapamycin (mTOR), tumor progression, cell cycle, and metastasis/angiogenesis were down-regulated. Serial changes in peretinoin-responsive gene expression are shown in Additional file 2: Figure S1. Significant changes in expression were observed in response to 600 mg of peretinoin, while changes in expression were minimal with 300 mg of peretinoin.

Hierarchical clustering of patients using hepatic gene expression profiling 8 weeks after peretinoin treatment could not be classified according to the dosage (Table 3). This might be because two patients treated with the 300 mg dosage (No. 11 and No. 12) had already expressed high levels of peretinoin-response genes before starting peretinoin treatment (Additional file 2: Figure S1). Interestingly, patients with high levels of peretinoin-response genes before treatment (No. 9–12) did not show HCC recurrence during the entire observation period (4.5 years; Table 1).

Hierarchical clustering of all 12 patients using 224 gene predictors is shown in Figure 2A. Clear gene clusters were observed according to patients with recurrence and those without, with the exception of one patient (No. 3, Table 1). Interestingly, in the liver of patients with non-recurrence, genes related to angiogenesis, cancer stem cells, Wnt signaling, and tumor progression were repressed, while genes inducing differentiation, tumor suppression, and apoptosis were up-regulated (Figure 2B, Table 4). Interestingly, PDGF-C was the most significant predictor to differentiate patients who will experience recurrence within 2 years (Table 4).

Consistent with these results, hierarchical clustering using pre-defined curated gene sets based on the NCBI’s Cancer Genome Anatomy Project similarly differentiated patients into two groups with or without HCC recurrence (Figure 3). Among angiogenesis-related genes, PDGF-C, PDGF-B, vascular endothelial growth factor (VEGF)-B, VEGF-D, and fibroblast growth factor-basic (FGF-2) were repressed in patients without recurrence. As for cell signaling-related genes, MYC, SRC, and RAS-related genes were also repressed; retinoid X receptor alpha (RXRA) and CCAAT/enhancer binding protein (C/EBP), alpha were up-regulated in patients without recurrence. Some cytokines (IL-7, IL-13, and IL-18) and chemokines (e.g. CXCL7) were repressed, while major histocompatibility complex molecules and interferon-related molecules (e.g. IFNAR2) were up-regulated in patients without recurrence (Figure 3).

cDNA microarray analysis revealed that among these predictors, the mRNA level of PDGF-C was the most significant predictor for differentiating patients who will experience recurrence within 2 years (Table 4). This observation was also assessed by RTD-PCR (Figure 4). The expression of the catalytic enzyme of retinoic acid, CYP26B1, was significantly up-regulated at around 200 fold by peretinoin treatment, but its expression was equally induced in patients with or without recurrence. However, the expression of RAR-β, a retinoid receptor, was significantly up-regulated by peretinoin in patients without HCC recurrence (Figure 4).

Patients were followed up for a further 3 years (mean: 2.5 ± 0.5 years) after the cessation of peretinoin treatment. Other two patients experienced recurrence during
Table 2 Representative genes significantly up-regulated or down-regulated in response to peretinoin treatment

| Parametric p-value | Ratios (Under/Pre) | Description | Symbol | GB acc  |
|--------------------|--------------------|-------------|--------|---------|
| **Up-regulated genes in response to peretinoin treatment** | | | | |
| | | | | |
| **Retinoid target genes** | | | | |
| 0.0002 | 1.85 | 1.25 | Cytochrome P450, family 26, subfamily B, polypeptide 1 | CYP26B1 | NM_019885 |
| 0.004  | 1.75 | 1.33 | Insulin-like growth factor binding protein 6 | IGFBP6 | NM_002178 |
| 0.005  | 1.42 | 1.16 | Regulatory factor X-associated ankyrin-containing protein | RFXANK | NM_134440 |
| 0.006  | 1.33 | 1.30 | Putative lymphocyte G0/G1 switch gene | G0S2 | NM_015714 |
| 0.013  | 1.54 | 0.90 | Retinol binding protein 1 | RBPI | NM_002899 |
| 0.014  | 1.56 | 0.87 | Retinol binding protein 4 | RBP4 | NM_006744 |
| 0.034  | 1.27 | 1.07 | Retinoic acid induced 3 | GPRC5A | A1023823 |
| 0.040  | 1.22 | 1.19 | Transglutaminase 2 | TGM2 | A1962033 |
| 0.044  | 1.23 | 1.14 | CCAAT/enhancer binding protein (C/EBP), alpha | CEBPA | NM_004564 |
| **Interferon-related genes** | | | | |
| 0.029  | 1.45 | 0.93 | Guanylate binding protein 1, interferon-inducible, 67kDa | GBP1 | NM_002053 |
| 0.047  | 1.39 | 0.94 | Interferon-induced protein 44 | IFI44 | NM_006417 |
| 0.048  | 1.28 | 1.05 | Chemokine (C-X-C motif) ligand 9 | CXCL9 | NM_002416 |
| **Negative regulator of Wnt and TGF-β signaling** | | | | |
| 0.004  | 1.54 | 1.06 | BMP and activin membrane-bound inhibitor homolog | BAMBI | NM_012342 |
| 0.008  | 1.45 | 1.11 | Secreted frizzled-related protein 5 | SFRPS | NM_003015 |
| **Anti-angiogenesis** | | | | |
| 0.021  | 1.37 | 0.98 | Thrombomodulin | THBD | NM_000361 |
| 0.038  | 1.28 | 0.99 | Protein C receptor, endothelial (EPCR) | PROCR | NM_006404 |
| **Tumor suppressor related** | | | | |
| 0.029  | 1.35 | 0.96 | Jumonji domain containing 3 | JMJD3 | XM_043272 |
| 0.029  | 1.39 | 0.91 | Jumping translocation breakpoint | JTB | NM_006694 |
| 0.034  | 1.39 | 1.32 | Protein kinase, AMP-activated, alpha 2 catalytic subunit | PRKAA2 | NM_006252 |
| **Down-regulated genes in response to peretinoin treatment** | | | | |
| **mTOR-related-gene** | | | | |
| 0.045  | 0.78 | 0.94 | FK506 binding protein 12-rapamycin associated protein 1 | FRAP1 | NM_004958 |
| **Cytokine and growth factor** | | | | |
| 0.019  | 0.77 | 1.25 | Interleukin 13 | IL13 | NM_002188 |
| 0.031  | 0.74 | 1.00 | Hepatocyte growth factor | HGF | NM_000601 |
| **Tumor progression related** | | | | |
| 0.011  | 0.73 | 0.94 | Junctional adhesion molecule 3 | JAM3 | NM_032801 |
| 0.013  | 0.70 | 1.00 | V-myc myelocytomatosis viral oncogene homolog | Myc | NM_002467 |
| 0.017  | 0.73 | 1.12 | Sec-like-adaptor | SLA | NM_006748 |
| 0.028  | 0.78 | 1.10 | Cell division cycle 2, G1 to S and G2 to M | CDC2 | NM_001786 |
| 0.030  | 0.66 | 0.95 | BCL2-associated athanogene | BAG1 | NM_004323 |
| 0.039  | 0.64 | 0.93 | Chemokine (C-C motif) receptor 9 | CCR9 | NM_012100 |
| 0.043  | 0.76 | 1.13 | Pre-B-cell leukemia transcription factor 1 | PBX1 | H08835 |

The peretinoin-response genes were identified by comparing hepatic gene expression in the pre and under treatment of 6 patients who were treated with 600 mg dose of peretinoin. The fold changes of gene expression are shown in 300 mg and 600 mg dosage respectively.
Trends in HCC recurrence and survival were identified. Patients with non-recurrence expression patterns were associated with improved survival compared to those with recurrence expression (P<0.002). Supervised learning methods identified 224 gene predictors for HCC recurrence. The Kaplan-Meier estimation of the recurrence-free ratio from these predictors showed significant differences in HCC recurrence between patients with recurrence expression patterns and those with non-recurrence expression (P=0.04). Moreover, Kaplan-Meier estimation of the survival ratio from the same gene predictors showed a trend for improved survival of patients with non-recurrence expression patterns compared to those with recurrence expression (P=0.12).

With the exception of the number of tumors at the time of curative therapy, none of the other clinical parameters (e.g., peretinoin dose, tumor, background liver histology, or background liver function) were associated with the recurrence-free or survival ratio. Thus, the peretinoin response during the early period of administration from the hepatic gene expression pattern can successfully predict HCC recurrence and, potentially, patient survival.

Discussion

Peretinoin [(2E,4E,6E,10E)-3,7,11,15-tetramethylhexadec-2,4,6,10,14-pentaenoic acid] is expected to be a powerful agent against HCC recurrence. This synthetic retinoid induces the transcriptional activation of the retinoic acid receptor (RAR) and retinoid X receptor (RXR), which are both members of the retinoid receptor family. One primary pathway of HCC development involves sustained hepatitis virus infection, which causes repeated cycles of hepatocellular necrosis and proliferation. During increased cell proliferation, mutations occur that lead to the development of HCC unless the dedifferentiated tumor cells are eliminated by apoptosis. The anti-HCC mechanism of action of peretinoin has previously been suggested to be a result of induction of cell apoptosis [20,21], enhancement of cell differentiation [21,22], suppression of cell proliferation by elevation of P21 protein expression and suppression of cyclin D1 expression [23,24]. The first route of action is independent of retinoid receptors, while the others are retinoid receptor-dependent, although all mechanisms remain largely speculative.

Peretinoin was previously shown to suppress in vivo hepatocarcinogenesis in 3'-methyl-4-dimethylaminooazobenzene- and N-diethylnitrosamine-induced rats [14,15,25], and in hepatoma-bearing mice and transgenic mice expressing a dominant-negative retinoic acid receptor [25,26]. Recently, we revealed that peretinoin effectively inhibits hepatic fibrosis and HCC development in Pdgf-c Tg mice. This demonstrated that PDGF signaling is a target of peretinoin in preventing the development of hepatic fibrosis and HCC [27]. The purpose of this study was to investigate how peretinoin exerts its therapeutic potential by analyzing its effects on the gene expression patterns in clinical samples.

Gene expression profiling in patients without HCC recurrence demonstrated the promotion of RAR-β expression, the most common retinoid target gene identified by basic research. Moreover, the expression of other retinoid target genes such as C/EBP-α, IGFBP6, TGM2, G0S2, RBP1, RBP4, and GPRCSA was also enhanced. Of these, C/EBP-α, IGFBP6, and TGM2 have been shown to inhibit HCC proliferation when co-expressed with RAR-β by all-trans-retinoic acid [28,29]. In addition, the RXR-selective agonist (retinoid)-induced expression of IGFBP6, which occurs following RAR-β-mediated transcriptional activation of RAR/RXR, has been shown to suppress tumor growth [30]. Moreover, G0S2 and GPRCSA have been reported to possess tumor suppressive or apoptosis-inducing effects [31,32]. These primary response retinoid target genes are presumably retinoid-responsive genes. In addition to enhancing retinoid target gene expression, peretinoin induced changes in the expression levels of a variety of genes involved in hepatocarcinogenesis, such as those related to Wnt signaling, IGF signaling, interferon, mTOR, and cell cycle regulation. These results suggest that peretinoin modulates multiple signaling cascades involved in carcinogenesis, either directly or indirectly. Abnormalities in the genes regulating Wnt signaling, IGF signaling, interferon, mTOR, and the cell cycle have been indicated to play a crucial role in the development of HCC [33,34]. We argue that peretinoin suppresses HCC cell proliferation by improving the expression of these genes, thereby preventing HCC recurrence.

The cluster analysis performed in this study successfully differentiated patients with recurrence within 2 years and those without it. Supervised learning methods identified 224 genes as predictors for HCC recurrence (p<0.002). Importantly, 44 (20%) of these were peretinoin-responsive genes, suggesting that recurrence-related genes might be regulated by peretinoin-responsive genes.

A comparison of these groups of patients revealed that the non-recurrence group was associated with the
enhanced expression of genes related to hepatocellular differentiation and tumor suppression. The non-recurrence group also showed reduced expression of the genes promoting liver fibrosis and steatosis and the liver cancer stem cell marker genes. The genes related to hepatocellular differentiation, \( MT1H \), \( MT2A \), \( FOXA1 \) (HNF3\( \alpha \)), and \( FOXA3 \) (HNF3\( \gamma \)), may be secondary response genes regulated by \( C/EBP-\alpha \) [35,36]. Indeed, \( C/EBP-\alpha \) manifested a significant shift in expression level before and during treatment with peretinoin, and could also differentiate between recurrence and non-recurrence within 2 years. Even after the cessation of peretinoin treatment, the expression of these genes was still significantly related to HCC recurrence (Figure 2C, D). Thus, we speculate that the differences in expression levels of peretinoin-response genes would determine the expression of recurrence-related genes (Additional file 3: Figure S2).

Interestingly, PDGF-C was the most significant predictor to differentiate those patients who will experience recurrence. Using a mouse model of PDGF-C over-expression, we determined that PDGF-C plays a critical role in the development of HCC recurrence. The expression of PDGF-C was significantly associated with HCC recurrence in both human and mouse models. Our findings suggest that PDGF-C could be a potential therapeutic target for preventing HCC recurrence.
expression resulting in hepatic fibrosis, steatosis, and eventually HCC development, peretinoin was previously shown to significantly repress the development of hepatic fibrosis and tumors [27].

Although gene expression profiling analysis was conducted using the remnant liver after definitive treatment in the present study, past similar research has demonstrated the possibility of predicting recurrent metachronous and multicentric HCC [37,38]. The exact mechanisms of how the expression profile of non-tumor tissues might determine the recurrence risk are not known. However, the degree of differentiation of hepatocytes and microenvironments such as angiogenesis and fibrogenesis in non-tumor lesions of the liver is likely to be closely associated with hepatocarcinogenesis. Interestingly, patients with pre-activated peretinoin-response genes were resistant to HCC recurrence for the entire observation period (4.5 years).

This study demonstrated that the patient response to peretinoin during the early period of administration could predict HCC recurrence and, potentially, patient survival. However, it should be noted that the current study protocol consisted of 600 mg peretinoin as the subsequent maintenance treatment for all patients after the 8-week start phase (Figure 1A). In addition, we did not conduct a placebo control to observe serial changes...
of hepatic gene expression without peretinoin administration. Therefore, there might be some limitations in drawing concrete conclusions from this study.

Although we attempted to analyze the liver peretinoin concentration in the present study to investigate its possible relationship with gene expression, peretinoin levels were too low to yield a meaningful result. However, considering that gene expression profiling identified significant changes in the expression levels of retinoid-related and other genes before and during peretinoin treatment, we believe that sufficient levels of peretinoin reached the liver.
Figure 4 RTD-PCR evaluation of PDGF-C, PROM1, MDK, CYP26B1, and RAR β in the liver of patients with or without HCC recurrence.
The previous peretinoin phase II/III clinical study demonstrated that daily doses of 600 mg peretinoin significantly reduced the incidence of HCC recurrence in HCV-positive patients who underwent definitive treatment. The findings of the present study are complementary to this as we successfully identified candidates for the peretinoin-responsive and recurrence-related genes. These genes are probably involved in the inhibition of HCC recurrence and could be beneficial as future candidate biomarkers of the effectiveness of peretinoin.

Conclusions
In this study, patients underwent liver biopsy before and after 8 weeks of treatment with repeated doses of peretinoin. Gene expression profiling at week 8 of peretinoin treatment could successfully predict HCC recurrence within 2 years. This study is the first to show the effect of peretinoin in suppressing HCC recurrence in vivo based on gene expression profiles and provides a molecular basis for understanding the efficacy of peretinoin.

Additional files

**Additional file 1:** Study protocol.

**Additional file 2:** Figure S1. One-way hierarchical clustering of up-regulated or down-regulated genes in the liver by the administration of peretinoin (300 mg and 600 mg). Changes in gene expression in the liver before the start of peretinoin administration and 8 weeks into the treatment are shown. Patients with HCC recurrence within 2 years are shown in red and those with HCC recurrence after the cessation of peretinoin are boxed in red.

**Additional file 3:** Figure S2. Schematic representation of peretinoin action in the liver.

**Abbreviations**
ACR: Acyclic Retinoid; CH-C: Chronic Hepatitis C; HCC: Hepatocellular Carcinoma; HCV: Hepatitis C Virus.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
MH: study concept and design, manuscript preparation. TY: gene expression analysis. KY: acquisition of data of clinical data. YS: gene expression analysis. AS: acquisition of data of clinical data. KS: acquisition of clinical data. SK: study concept and design. All authors read and approved the final manuscript.

Acknowledgements
The authors thank Nami Nishiyama for excellent technical assistance. This work was supported in part by KOWA Co. Ltd., Tokyo, Japan.

Received: 13 September 2012 Accepted: 8 March 2013
Published: 15 April 2013

References
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893–2917.
2. Atrekruse SF, McGlynn KA, Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009, 27(9):1485–1491.
3. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003, 362(9399):1907–1917.
4. Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19(3):329–338.
5. Mazzaferr V, Regalia E, Doci R, Andreola S, Pulvirent A, Bozzetti F, Montalto F, Amatucci M, Morabito A, Gennari L: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334(11):693–699.
6. Llovet JM, Schwartz M, Mazzaferr V: Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005, 25(2):181–200.
7. Castells A, Bruix J, Bru C, Fuster J, Vilana R, Navasa M, Ayuso C, Boix L, Visa J, Rodes J: Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology 1993, 18(5):1121–1126.
8. Shiratori Y, Shinia S, Teratani T, Imanura M, Ohi S, Sato S, Koike Y, Yoshida H, Omata M: Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003, 138(4):299–306.
9. Breitenstein S, Dimitroulis D, Petrovsky H, Puchan IA, Mullhaupt B, Clavien PA: Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 2009, 96(9):975–981.
10. Samuel M, Chow PK, Chan Shih-Yen E, Machin D, Soo KC: Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev 2009, 1:CD001199.
11. Mathurin P, Raynard B, Dharnary S, Kizian S, Fallik D, Pruvot FR, Roumlid D, Carna V, Paris X, Chaput JC, et al: Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma. Aliment Pharmacol Ther 2003, 17(10):1247–1263.
12. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, Tanaka T, Tsurumi K, Okuno M, Tomita E, et al: Prevention of second primary tumors by an acyclic retinoid, polyphenolic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996, 334(24):1561–1567.
13. Muto Y, Moriwaki H, Saito A: Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 1999, 340(13):1046–1047.
14. Sano T, Kagawa M, Okuno M, Ishibashi N, Hashimoto M, Yamamoto M, Suzuki R, Kohn H, Matsuhashi-Nishiwaki R, Takano Y, et al: Prevention of rat hepatocarcinogenesis by acyclic retinoid is accompanied by reduction in emergence of both TGF-alpha-expressing oval-like cells and activated hepatic stellate cells. Nutr Cancer 2005, 51(2):197–206.
15. Kagawa M, Sano T, Ishibashi N, Hashimoto M, Okuno M, Moriwaki H, Suzuki R, Kohn H, Tanaka T: An acyclic retinoid, NIK-333, inhibits N-diethylnitrosamine-induced rat hepatocarcinogenesis through suppression of TGF-alpha expression and cell proliferation. Carcinogenesis 2004, 25(6):979–985.
16. Okusaka T, Ueno H, Ikei M, Morizane C: Phase I and pharmacokinetic clinical trial of oral administration of the acyclic retinoid NIK-333. Hepatol Res 2011, 41(6):542–552.
17. Okita K, Matsui O, Kumada H, Tanaka K, Kaneko S, Moriwaki H, Izumi N, Okusaka T, Ohashi Y, Makuuchi T: Effect of peretinoin on recurrence of hepatocellular carcinoma (HCC): Results of a phase II/III randomized placebo-controlled trial. J Clin Oncol 2010, 28(15s):4024/4024.
18. Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Kaneko S: Different signaling pathways in the livers of patients with chronic hepatitis B or chronic hepatitis C. Hepatology 2006, 44(3):1122–1138.
19. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shirasaki T, Horimoto K, et al: Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010, 138(2):499–509.
20. Nakamura N, Shioda Y, Yamada Y, Hatakayama H, Moriwaki H, Muto Y: Induction of apoptosis by acyclic retinoid in the human hepatoma-derived cell line, HuH-7. Biochem Biophys Res Commun 1995, 207(1):382–388.
21. Yasuda I, Shiratori Y, Adachi S, Obara T, Takemura M, Okuno M, Shioda Y, Seishima M, Muto Y, Moriwaki H: Acyclic retinoid induces partial differentiation, down-regulates telomerase reverse transcriptase mRNA
expression and telomerase activity, and induces apoptosis in human hepatoma-derived cell lines. J Hepatol 2002, 36(5):660–671.
22. Yamada Y, Shidooji Y, Fukutomi Y, Ishikawa T, Kaneko T, Nakagama H, Imawari M, Moriwaki H, Muto Y: Positive and negative regulations of albumin gene expression by retinoids in human hepatoma cell lines. Mol Carcinog 1994, 10(3):151–158.
23. Suzuki M, Masuda M, Lim JT, Albanese C, Pestell RG, Weinstein IB: Growth inhibition of human hepatoma cells by acyclic retinoid is associated with inhibition of p21(CIP1) and inhibition of expression of cyclin D1. Cancer Res 2002, 62(14):3997–4006.
24. Suzuki M, Shindo M, Masuda M, Lim JT, Yoshimi N, Weinstein IB: Acyclic retinoid activates retinoic acid receptor beta and induces transcriptional activation of p21(CIP1) in HepG2 human hepatoma cells. Mol Cancer Ther 2004, 3(3):309–316.
25. Muto Y, Moriwaki H: Anti-tumor activity of vitamin A and its derivatives. J Natl Cancer Inst 1984, 73(6):1389–1393.
26. Sakabe T, Tsuchiya H, Endo M, Tomita A, Ishii K, Gonda K, Murai R, Takubo K, Hoshikawa Y, Kurimasa A, et al: An antioxidant effect by acyclic retinoid suppresses liver tumor in mice. Biochem Pharmacol 2007, 73(5):1425–1431. Imawari M, Moriwaki H, Muto Y: An antioxidant effect by acyclic retinoid suppresses liver tumor in mice. Biochem Pharmacol 2007, 73(5):1425–1431.
27. Okada H, Honda M, Campbell JS, Yamashita T, Takebuchi Y, Hada K, Shirasaki T, Takabatake R, Nakamura M, et al: Acyclic retinoid targets platelet-derived growth factor signaling in the prevention of hepatic fibrosis and hepatocellular carcinoma development. Cancer Res 2012, 72(17):4459–4467.
28. Tomaru Y, Nakashita M, Miura H, Hayashizaki Y, Suzuki M: Identification of an inter-transcription factor regulatory network in human hepatoma cells by Matrix RINAI. Nucleic Acids Res 2009, 37(4):1049–1060.
29. Nakashita M, Tomaru Y, Miura H, Hayashizaki Y, Suzuki M: Identification of transcriptional regulatory cascades in retinoic acid-induced growth arrest of HepG2 cells. Nucleic Acids Res 2008, 36(10):3443–3454.
30. Uray IP, Shen Q, Seo HS, Kim H, Lamph WW, Bissisonne RP, Brown PH: Rexitoid-induced expression of IGFBP-6 requires RARbeta-dependent permissive cooperation of retinoid receptors and AP-1. J Biol Chem 2009, 284(1):345–353.
31. Ma Y, Koza-Taylor PH, DiMattia DA, Hames L, Fu H, Dragnev KH, Turi T, Beebe JS, Freemantle SJ, Dmitrovsky E: Microarray analysis uncovers retinoid targets in human bronchial epithelial cells. Oncogene 2003, 22(31):4924–4932.
32. Ye X, Tao Q, Wang Y, Cheng Y, Lotan R: Mechanisms underlying the induction of the putative human tumor suppressor GPRCSA by retinoic acid. Cancer Biol Ther 2009, 8(10):951–962.
33. Llovet JM: Brux J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008, 48(4):1312–1327.
34. Zender L, Villanueva A, Tovar V, Sia D, Costa R, Cha HC, Fields AL, Soprano DR, Soprano KJ: Retinoids in biological control and cancer. J Cell Biochem 2007, 102(4):886–896.
35. Hoshikawa Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, MacDougald OA, Jacob ST, Ghoshal K: Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade. Cancer Res 2007, 67(6):2736–2746.
36. Fields AL, Soprano DR, Soprano KJ: Retinoids in biological control and cancer. J Cell Biochem 2007, 102(4):886–896.
37. Zender L, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, et al: Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008, 359(19):1995–2004.
38. Utsunomiya T, Shimada M, Imura S, Morine Y, Ikemoto T, Mori M: Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma. J Gastroenterol 2010, 45(2):146–152.

Cite this article as: Honda et al: Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma. BMC Cancer 2013 13:191.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit